# 24-hour IOP-lowering Effect of Brimonidine 0.1%

> **NCT00457795** · PHASE4 · COMPLETED · sponsor: **Allergan** · enrollment: 15 (actual)

## Conditions studied

- Open-angle Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** brimonidine 0.1% (Alphagan® P)

## Key facts

- **NCT ID:** NCT00457795
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2009-02
- **Final completion:** 2009-02
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2011-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00457795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00457795, "24-hour IOP-lowering Effect of Brimonidine 0.1%". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00457795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*